SET protein as an epigenetics target

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Di Mambro A, Esposito MT. Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer's disease. Biosci. Rep. 42(11), BSR20221280 (2022).
  MedlineGoogle Scholar
• 2. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6(8), 227 (2005).
  MedlineGoogle Scholar
• 3. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′-half to different genes: characterization of the set gene. Mol. Cell Biol. 12(8), 3346–3355 (1992).
  Medline CASGoogle Scholar
• 4. Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J. Biol. Chem. 269(3), 2258–2262 (1994). •• One of the most important references as it was the first to describe the identification of SET in an acute undifferentiated leukemia patient and elucidates the characterization of this protein including localization, molecular mass and its phosphorylation.
  Medline CASGoogle Scholar
• 5. Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34(6), 1988–1996 (1995). • Demonstrates that the finding of PP2A inhibitors originate from bovine kidney, being the most known function correlated to SET.
  Medline CASGoogle Scholar
• 6. Zheng HY, Shen FJ, Tong YQ, Li Y. PP2A inhibits cervical cancer cell migration by dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK signaling pathway. Curr. Med. Sci. 38(1), 115–123 (2018).
  Medline CASGoogle Scholar
• 7. Richard NP, Pippa R, Cleary MM et al. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget 7(51), 84214–84227 (2016).
  MedlineGoogle Scholar
• 8. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 112(5), 659–672 (2003).
  Medline CASGoogle Scholar
• 9. Chae YC, Kim KB, Kang JY, Kim SR, Jung HS, Seo SB. Inhibition of FoxO1 acetylation by INHAT subunit SET/TAF-Iβ induces p21 transcription. FEBS Lett. 588(17), 2867–2873 (2014).
  Medline CASGoogle Scholar
• 10. Okuwaki M, Nagata K. Template activating factor-I remodels the chromatin structure and stimulates transcription from the chromatin template. J. Biol. Chem. 273(51), 34511–34518 (1998). •• The first to identify TAF-1 interacting with histones and chromatin remodeling, TAF-1 being identified as SET.
  Medline CASGoogle Scholar
• 11. Kalousi A, Hoffbeck AS, Selemenakis PN et al. The nuclear oncogene SET controls DNA repair by KAP1 and HP1 retention to chromatin. Cell Rep. 11(1), 149–163 (2015).
  Medline CASGoogle Scholar
• 12. Nenasheva VV, Makarova IV, Stepanenko EA et al. Human TAF-Iα promotes oncogenic transformation via enhancement of cell proliferation and suppression of apoptosis. In Vitro Cell Dev. Biol. Anim. 57(5), 531–538 (2021).
  Medline CASGoogle Scholar
• 13. Cristóbal I, Blanco FJ, Garcia-Orti L et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 115(3), 615–625 (2010).
  Medline CASGoogle Scholar
• 14. Yin L, Zeng Y, Xiao Y, Chen Y, Shen H, Dong J. Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity. Cell Death Dis. 10(6), 385 (2019).
  MedlineGoogle Scholar
• 15. Arriazu E, Vicente C, Pippa R et al. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia. Blood Cancer J. 10(1), 3 (2020).
  MedlineGoogle Scholar
• 16. Han D, Wang L, Long L et al. The E3 ligase TRIM4 facilitates SET ubiquitin-mediated degradation to enhance ER-α action in breast cancer. Adv. Sci. (Weinh.) 9(25), e2201701 (2022).
  Medline CASGoogle Scholar
• 17. Pippa R, Dominguez A, Malumbres R et al. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia. Oncotarget 8(33), 53989–54003 (2017).
  MedlineGoogle Scholar
• 18. Asaka MN, Murano K, Nagata K. Sp1-mediated transcription regulation of TAF-Ialpha gene encoding a histone chaperone. Biochem. Biophys Res. Commun. 376(4), 665–670 (2008).
  Medline CASGoogle Scholar
• 19. Pan H, Pan Z, Guo F et al. MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer. BMC Cancer 21(1), 1218 (2021). • Recent article discussing the relationship between miR-1915-3p and SET in non-small-cell lung cancer and shows the epigenetic mechanisms of miRNAs that are able to regulate SET protein.
  Medline CASGoogle Scholar
• 20. Chao A, Tsai CL, Wei PC et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett. 291(1), 99–107 (2010). •• One of the first studies to describe miRNA regulation of SET levels. Specifically, when miR-199b is diminished, SET protein levels increase in choriocarcinoma.
  Medline CASGoogle Scholar
• 21. Jiang W, Wen D, Gong L, Wang Y, Liu Z, Yin F. Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET. Biochem. Biophys Res. Commun. 500(2), 211–216 (2018).
  Medline CASGoogle Scholar
• 22. Hu YP, Jin YP, Wu XS et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis. Mol. Cancer 18(1), 167 (2019).
  Medline CASGoogle Scholar
• 23. Zhong J, Ren X, Chen Z et al. miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-Iα. Life Sci. 231, 116539 (2019).
  Medline CASGoogle Scholar
• 24. Ying X, Wei K, Lin Z et al. MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein. Cell Physiol. Biochem. 39(2), 501–510 (2016).
  Medline CASGoogle Scholar
• 25. Zhang L, Zhang J, Xuan X et al. A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression. Cell Rep. 42(8), 112833 (2023). •• Regarding our focus on epigenetics, this article discusses the new identification of SET-p53, which is affected by a long-noncoding RNA (LINC00324) in lung and breast cancer.
  Medline CASGoogle Scholar
• 26. Liu R, Wang JZ. Protein phosphatase 2A in Alzheimer's disease. Pathophysiology 16(4), 273–277 (2009).
  MedlineGoogle Scholar
• 27. Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 166(6), 1761–1771 (2005).
  Medline CASGoogle Scholar
• 28. Qin M, Li H, Bao J et al. SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments. Acta Neuropathol. Commun. 7(1), 21 (2019).
  MedlineGoogle Scholar
• 29. Kim DW, Kim KB, Kim JY, Lee KS, Seo SB. Negative regulation of neuronal cell differentiation by INHAT subunit SET/TAF-Iβ. Biochem. Biophys Res. Commun. 400(3), 419–425 (2010).
  Medline CASGoogle Scholar
• 30. Serifi I, Besta S, Karetsou Z et al. Targeting of SET/I2PP2A oncoprotein inhibits Gli1 transcription revealing a new modulator of Hedgehog signaling. Sci. Rep. 11(1), 13940 (2021).
  Medline CASGoogle Scholar
• 31. Edupuganti RR, Harikumar A, Aaronson Y et al. Alternative SET/TAFI promoters regulate embryonic stem cell differentiation. Stem Cell Reports 9(4), 1291–1303 (2017).
  Medline CASGoogle Scholar
• 32. Yuan X, Wang X, Gu B et al. Directional migration in esophageal squamous cell carcinoma (ESCC) is epigenetically regulated by SET nuclear oncogene, a member of the inhibitor of histone acetyltransferase complex. Neoplasia 19(11), 868–884 (2017). • Reports that miR-30c is epigenetically regulated by SET and has an impact on migration and metastasis in an esophageal squamous cell carcinoma model.
  Medline CASGoogle Scholar
• 33. Luo XG, Zhang CL, Zhao WW et al. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. Cancer Lett. 344(1), 129–137 (2014).
  Medline CASGoogle Scholar
• 34. Azad GK, Swagatika S, Kumawat M, Kumawat R, Tomar RS. Modifying chromatin by histone tail clipping. J. Mol. Biol. 430(18 Pt B), 3051–3067 (2018).
  Medline CASGoogle Scholar
• 35. Cai LY, Chen SJ, Xiao SH et al. Targeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Res. 81(4), 860–872 (2021).
  Medline CASGoogle Scholar
• 36. González-Arzola K, Guerra-Castellano A, Rivero-Rodríguez F et al. Mitochondrial cytochrome C shot towards histone chaperone condensates in the nucleus. FEBS Open Bio. 11(9), 2418–2440 (2021).
  Medline CASGoogle Scholar
• 37. Saavedra F, Rivera C, Rivas E et al. PP32 and SET/TAF-Iβ proteins regulate the acetylation of newly synthesized histone H4. Nucleic Acids Res. 45(20), 11700–11710 (2017).
  Medline CASGoogle Scholar
• 38. Xia Z, Kon N, Gu AP, Tavana O, Gu W. Deciphering the acetylation code of p53 in transcription regulation and tumor suppression. Oncogene 41(22), 3039–3050 (2022).
  Medline CASGoogle Scholar
• 39. Kim JY, Lee KS, Seol JE, Yu K, Chakravarti D, Seo SB. Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity. Nucleic Acids Res. 40(1), 75–87 (2012).
  Medline CASGoogle Scholar
• 40. Wang D, Kon N, Lasso G et al. Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature 538(7623), 118–122 (2016).
  Medline CASGoogle Scholar
• 41. Kim KB, Kim DW, Park JW et al. Inhibition of Ku70 acetylation by INHAT subunit SET/TAF-Iβ regulates Ku70-mediated DNA damage response. Cell Mol. Life Sci. 71(14), 2731–2745 (2014).
  Medline CASGoogle Scholar
• 42. Seibert M, Krüger M, Watson NA et al. CDK1-mediated phosphorylation at H2B serine 6 is required for mitotic chromosome segregation. J. Cell Biol. 218(4), 1164–1181 (2019).
  Medline CASGoogle Scholar
• 43. Sousa LO, Sobral LM, de Almeida LO, Garcia CB, Greene LJ, Leopoldino AM. SET protein modulates H4 histone methylation status and regulates miR-137 level in oral squamous cell carcinoma. Epigenomics 12(6), 475–485 (2020).
  CASGoogle Scholar
• 44. Kato K, Kawaguchi A, Nagata K. Template activating factor-I epigenetically regulates the TERT transcription in human cancer cells. Sci. Rep. 11(1), 17726 (2021).
  Medline CASGoogle Scholar
• 45. Almeida LO, Neto MPC, Sousa LO, Tannous MA, Curti C, Leopoldino AM. SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget 8(16), 26802–26818 (2017). • One of the only articles demonstrating a DNA demethylation mechanism correlating with SET protein.
  MedlineGoogle Scholar
• 46. Revil T, Pelletier J, Toutant J, Cloutier A, Chabot B. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J. Biol. Chem. 284(32), 21458–21467 (2009).
  Medline CASGoogle Scholar
• 47. Almeida LO, Garcia CB, Matos-Silva FA, Curti C, Leopoldino AM. Accumulated SET protein up-regulates and interacts with hnRNPK, increasing its binding to nucleic acids, the Bcl-xS repression, and cellular proliferation. Biochem. Biophys Res. Commun. 445(1), 196–202 (2014).
  Medline CASGoogle Scholar
• 48. Lynch KL, Dillon MR, Bat-Erdene M et al. A viral histone-like protein exploits antagonism between linker histones and HMGB proteins to obstruct the cell cycle. Curr. Biol. 31(23), 5227–5237; e5227 (2021).
  Medline CASGoogle Scholar